// you’re reading...

General Biotechnology

FDA’s economist in chief

By Yali ⋅ January 21, 2004 ⋅ Email This Post Email This Post ⋅ Print This Post Print This Post ⋅ Post a comment

FDA’s economist in chief
Foes and friends of Mark McClellan agree on at least one point: The Food and Drug Administration commissioner is very popular with the drug industry he regulates. This article profiles opinions of Mark McClennan’s performance as FDA commissioner.

Print This Post

Discussion

No comments for “FDA’s economist in chief”

Post a comment

Building Biotechnology - Starting, Managing, and Understanding Biotechnology Companies   The Business of Biotechnology - Profit From the Growing Influence of Biotechnology
Best Practices in Biotechnology Business Development Best Practices in Biotechnology Education
Journal of Commercial Biotechnology 
DrugPatentWatch.com